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Abstract
Adipocyte and b-cell dysfunction and macrophage-related chronic inflammation are critical for the development of obesity-
related insulin resistance and type 2 diabetes mellitus (T2DM), which can be negatively regulated by Tregs. Our previous
studies and those of others have shown that activation of c-aminobutyric acid (GABA) receptors inhibits inflammation in
mice. However, whether GABA could modulate high fat diet (HFD)-induced obesity, glucose intolerance and insulin
resistance has not been explored. Here, we show that although oral treatment with GABA does not affect water and food
consumption it inhibits the HFD-induced gain in body weights in C57BL/6 mice. Furthermore, oral treatment with GABA
significantly reduced the concentrations of fasting blood glucose, and improved glucose tolerance and insulin sensitivity in
the HFD-fed mice. More importantly, after the onset of obesity and T2DM, oral treatment with GABA inhibited the continual
HFD-induced gain in body weights, reduced the concentrations of fasting blood glucose and improved glucose tolerance
and insulin sensitivity in mice. In addition, oral treatment with GABA reduced the epididymal fat mass, adipocyte size, and
the frequency of macrophage infiltrates in the adipose tissues of HFD-fed mice. Notably, oral treatment with GABA
significantly increased the frequency of CD4
+Foxp3
+ Tregs in mice. Collectively, our data indicated that activation of
peripheral GABA receptors inhibited the HFD-induced glucose intolerance, insulin resistance, and obesity by inhibiting
obesity-related inflammation and up-regulating Treg responses in vivo. Given that GABA is safe for human consumption,
activators of GABA receptors may be valuable for the prevention of obesity and intervention of T2DM in the clinic.
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Introduction
Obesity is associated with the development of type 2 diabetes
mellitus (T2DM) and stems from the imbalance between calorie
intake and expenditure, as well as genetic factors, leading to the
accumulation of excess fat in the body. T2DM is characterized by
impaired glucose tolerance, insulin resistance and insufficient
insulin production by the pancreatic islet b-cells [1,2]. The
incidence of obesity-related T2DM is dramatically increasing
worldwide. Individuals with obesity and T2DM are at risk of
developing micro- and macrovascular diseases, such as hyperten-
sion, cardiovascular diseases and cerebovascular diseases [3,4].
Although many medications are available for the management of
hyperlipidemia and hyperglycemia, they fail to completely restore
glucose homeostasis and/or have adverse effects. Therefore, the
discovery and development of new reagents that can safely inhibit
obesity development and improve glucose metabolism will be of
great benefit for slowing the development of T2DM and limiting
its long-term complications.
Previous studies have shown that adipocyte and b-cell
dysfunction along with low-grade macrophage-related chronic
inflammation are critical for the development of obesity-related
insulin resistance and T2DM [2,5,6,7,8]. During the development
of obesity and T2DM, adipocytes can produce adipokines and
other factors, which recruit the infiltration of macrophages and
other immunocompetent cells into the adipose tissues and affect
insulin sensitivity in other organs, leading to low grade
inflammation [9,10,11]. Apparently, inhibition of chronic inflam-
mation and macrophage infiltration may inhibit adipocyte
hypertrophy and improve glucose tolerance and insulin sensitivity.
Indeed, regulatory T cells (Tregs) have been shown to inhibit the
high fat diet (HFD)-induced adipocyte dysfunction, glucose
intolerance, and insulin resistance in mice [12]. Notably, GABAA
receptors (GABAA-R) are expressed by adipose tissues and
immunocompetent cells, such as macrophages and T cells
[13,14,15]. Our previous studies and those of others have shown
that activation of GABAA-R inhibits inflammatory diseases, such
as type 1 diabetes (T1D), experimental autoimmune encephalo-
myelitis (EAE), collagen-induced rheumatoid arthritis (RA) in mice
and prolongs the survival of syngenic islet grafts in diabetic NOD
mice [16,17,18,19,20]. A recent study as well as our unpublished
observations show that GABA promotes regeneration of the
pancreatic b-cells and reverses hyperglycemia in the mouse model
of T1D [20]. Accordingly, it is possible that activation of GABA
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and inflammation, as well as associated obesity and glucose
metabolic disorder.
To test this hypothesis, we employed the HFD-induced obesity
and T2DM model and treated orally with GABA to test whether
activation of GABA receptors could prevent the HFD-induced
obesity and T2DM, and improve glucose tolerance and insulin
sensitivity after the onset of T2DM. We found that oral
administration of GABA did not affect the amount of water and
food consumption by animals, but reduced the HFD-induced gain
in body weight and epididymal fat mass, accompanied by reducing
the numbers of infiltrated macrophages in adipose tissues.
Furthermore, treatment with GABA improved glucose tolerance
and insulin sensitivity in mice, even after the onset of obesity and
T2DM. Finally, we observed that treatment with GABA
significantly increased the frequency of peripheral Tregs in mice,
which are known to negatively regulate inflammation.
Materials and Methods
Mice and treatments
All experiments were approved by the Animal Research
Committee of University of California, Los Angeles (protocol
number 1993-211). Male C57BL/6 mice at 4 weeks of age were
from Jackson Laboratories (Bar Harbor, ME, USA) and were
housed in a specific pathogen free facility. The mice were fed with
HFD beginning at 5 weeks of age (60% fat of caloric intake at
5.32 kcal/g, Research Diets, New Brunswick, USA) and provided
with plain water (control) or water containing 2 mg/ml of GABA
(Sigma, St. Louis, USA). The water bottles were changed weekly
with fresh material. Their food intake and water consumption
were measured weekly and their body weights, fasting blood
glucose, glucose tolerance, and insulin sensitivity were measured
longitudinally.
In addition, we tested whether treatment with GABA could
modulate glucose intolerance and insulin resistance in mice after
the onset of obesity and T2DM. C57BL/6 mice were fed with
HFD and plain water for 20 weeks and tested for fasting blood
glucose, glucose tolerance, and insulin sensitivity. Individual mice
with obesity (body weights . 48 g) and T2DM (fasting blood
glucose .145 mg/dL; blood glucose at 2 hours post-intraperito-
neal glucose challenge .220 mg/dL; blood glucose at 30 min post
insulin injection , 28% before insulin injection) were randomly
divided and fed with HFD and plain water or water containing
2 mg of GABA for another 12 weeks, respectively. Their food
intake and water consumption were measured weekly and their
body weights, fasting blood glucose, glucose tolerance, and insulin
sensitivity were measured longitudinally.
Measurement of fasting blood glucose, glucose
tolerance, and insulin sensitivity
The mice were fasted for 16 hours and the concentrations of
blood glucose in individual mice were measured using an
OneTouch ultra blood glucose meter (LifeScan, Milpitas, USA).
Glucose tolerance in individual mice was injected intraperitoneally
with 2 g/kg glucose (Sigma) and their blood glucose concentra-
tions were measured at 15, 30, 60, 90, 120 and 180 min post
challenge and the areas of under the curve (AUC) of blood glucose
levels were calculated. For insulin tolerance tests, non-fasted
individual mice were measured for the concentrations of blood
glucose as 0 time point and injected intraperitoneally with 0.75
units/kg of human regular insulin (Eli Lilly, Indianapolis, USA).
Subsequently, the concentrations of blood glucose were measured
at 15, 30, 60, 90, 120 and 150 min post insulin injection. The
changes in the percentage of blood glucose relative to the values at
0 time point for individual mice were calculated.
Histological analysis of visceral adipose tissue
At the end of the experiments, mice were sacrificed and their
visceral adipose tissue (VAT) were dissected and weighed. One
portion of the VAT was fixed with 4% paraformaldehyde for
24 hours and the VAT sections at 5 mm were stained with
Toluidine blue O. A total 5 sections from individual mice of each
group (n=8) were examined in a blinded fashion using the Lplab
image analysis software.
Another portion of the VAT was fixed with the Bouin buffer for
48 hours and then paraffin-embedded. Their sections at 5 mmo f
100 mm intervals were rehydrated, treated with 3% of H202 in
methanol, and subjected to antigen retrieval with 0.01 M sodium
citrate buffer (pH 6.0) in a high pressure-steamer. Subsequently,
these sections were blocked sequentially with a biotin blocking
system (Dako) and 20% of FBS in PBS. The sections were probed
with biotinylated anti-F4/80 (PharMigen, San Diego, USA)
overnight at 4uC. After washing, the immunocomplex was
visualized using HRP-striptoavidin (Dako) and the peroxidase
substrate diaminobenzidine (DAB, Dako), followed by counter-
staining with hematoxylin and examination under a light
microscope. A total of 400 nuclei from 5 fields of 5 sections of
each mouse were counted in a blinded manner and the percentage
of macrophage infiltrates was calculated.
Flow cytometry analysis
Groups of C57BL/6 mice were fed with plain water or water
containing 2 mg/ml of GABA for 4 weeks. Their splenic
mononuclear cells were prepared and the frequency of
CD4
+Foxp3
+ Tregs was characterized by flow cytometry analysis.
Briefly, splenic mononuclear cells (10
6/tube) were treated in
duplicate with anti-CD16/32 on ice for 20 minutes. After washing,
the cells were stained with FITC-anti-CD4 (BD PharMigen, San
Diego, USA) for 25 minutes, fixed, permeabilized and stained with
PE-anti-Foxp3 or isotype control (Biolegend, San Diego. USA),
respectively. After washing, the cells were characterized by flow




+ T cells was calculated.
Statistical analysis
Data are expressed as mean or mean 6 SD of each group of
mice. The difference between groups was analyzed by Students’ t-
test and X
2 test. The potential correlation between measures was
analyzed by Sperman’s correlation analysis. A p value of less than
0.05 was considered statistically significant.
Results
Oral treatment with GABA does not change the amounts
of water and food consumed, but significantly reduces
the gain of body weight in HFD-fed mice
GABAA-R subunits are expressed by immunocompetent cells,
including T cells and macrophages and are also expressed by
adipose tissues [13,14,15,17]. Our previous studies and those of
others have shown that treatment with GABA or a GABAA
receptor agonist inhibits inflammation in different mouse models
of autoimmune diseases [16,17,18,20,21]. To determine whether
GABA could modulate HFD-induced inflammation, obesity, and
glucose intolerance, groups of 5-week-old male C57BL/6 mice
were fed with HFD and provided with plain water or water
containing 2 mg/ml of GABA for 20 weeks. Their food and water
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significant difference in the mean amount of food intake and water
consumption of individual mice between the water and GABA-
treated groups of mice, consistent with our previous observations
in a RA-prone stain of mice [18]. Although the body weights of
individual mice in both groups of mice gradually increased
following HFD-feeding, the mean body weights in the GABA-
treated mice at 10 weeks post GABA treatment were significantly
less than that of the water-fed mice (Fig. 1C) and remained
significantly less than that of controls throughout the subsequent
observation period. These data indicated that oral treatment with
GABA did not significantly alter the food and water consumption,
but reduced the HFD-associated gain in mouse body weight.
Oral treatment with GABA improves glucose tolerance
and insulin sensitivity in HFD-fed mice
During the study period, we measured the concentrations of
fasting blood glucose, glucose tolerance and insulin sensitivity in
the water-fed control and GABA-fed mice longitudinally. We
found that the concentrations of fasting blood glucose gradually
increased in control mice and some mice at 20 weeks post HFD
developed T2DM. In contrast, the concentrations of fasting blood
glucose in mice that received GABA remained at a similar level
throughout the observation period (Fig. 2A). As a result, the
concentrations of fasting blood glucose in the GABA-fed mice
were significantly lower than that of controls at 9 weeks post HFD
(p,0.05). Similarly, oral feeding with GABA inhibited the
development of glucose intolerance in the HFD-fed mice
(Fig. 2B). Furthermore, while challenge of the control mice with
insulin only resulted in moderate reduction in the concentrations
of blood glucose, an indication of insulin resistance, challenge with
insulin dramatically reduced the concentrations of blood glucose in
the GABA-fed mice. Together, these data clearly demonstrated
that oral treatment with GABA inhibited the HFD-induced
glucose intolerance and insulin resistance in mice.
Treatment with GABA improves glucose tolerance and
insulin sensitivity in mice after the onset of obesity and
T2DM
To test whether treatment with GABA could modulate glucose
tolerance and insulin sensitivity in mice after the onset of obesity
and T2DM, C57BL/6 mice were fed with HFD for 20 weeks and
their fasting glucose, glucose tolerance, and insulin sensitivity were
measured. Individual mice with obesity (body weight . 48 g) and
T2DM (abnormal fasting blood glucose and impaired glucose
tolerance and insulin sensitivity, see Materials and Methods) were
randomized and fed with water as controls or with water
containing GABA (2 mg/ml) for another 12 weeks. Their body
weights, fasting blood glucose levels, glucose tolerance, and insulin
sensitivity were measured longitudinally. As shown in Fig. 3, mice
that had been continually fed with HFD and plain water gradually
increased their body weights while the mice fed with HFD and
water containing GABA gained little or no body weight (Fig. 3A).
More importantly, following treatment with GABA, all of diabetic
mice became euglycemic and the mean concentrations of fasting
blood glucose in the GABA-treated mice were significantly lower
than that of controls at 32 weeks post HFD (p,0.05, Fig. 3B). In
addition, treatment with GABA improved glucose intolerance and
insulin sensitivity in the HFD-fed mice (Fig. 3C and D). While
both groups of mice displayed similar levels of peak blood glucose
after glucose challenge, the GABA-treated mice exhibited near
normal levels of blood glucose at 2 hour post glucose challenge. In
contrast, the concentrations of blood glucose at 2-hour post
glucose challenge in the plain water-fed mice remained hypergly-
cemic. Moreover, while insulin challenge reduced the concentra-
tions of blood glucose by less than 25% in the plain water-fed mice
the same treatment dramatically reduced the concentrations of
blood glucose by nearly 50% during the early stages of responding
to insulin in the GABA-treated mice. Therefore, treatment with
GABA improved glucose intolerance and insulin sensitivity in the
mice with established obesity and T2DM.
Treatment with GABA reduces adipocyte mass and
macrophage infiltration in the adipose tissues of HFD-fed
mice
Previous studies have shown that macrophage-related chronic
inflammation in adipose tissues is crucial for the development of
insulin resistance, obesity, and T2DM [1,22]. Given that GABAA-
R subunits are expressed by macrophages and adipose tissues
[13,15], we further tested whether GABA could modulate
macrophage-associated inflammation in adipose tissues, or alter
adipose tissue mass in the HFD-fed mice. Following HFD feeding
for 20 weeks, control and GABA-treated mice were sacrificed and
their VAT was dissected out and weighed. The total amount of
VAT in the GABA-treated mice was significantly less than that of
the controls (Fig. 4A), consistent with reduced body weights.
Further analysis of VAT revealed that the size of adipocytes in the
GABA-treated mice was also significantly less than that of the
Figure 1. Oral treatment with GABA does not alter the amounts of water and food consumed, but reduces the gain of body weights
in the HFD-fed mice. Groups of C57BL/6 mice were fed with HFD and provided with plain water or water containing 2 mg/ml of GABA for 20
weeks. The amounts of water and food consumed by individual mice and their body weights were measured longitudinally. Data are expressed as
mean values of water and food consumed by individual mice per day and mean values of body weights of each group of mice (n=20 per group) at
the indicated time points post-HFD. Intragroup variations were less than 10% for the amounts of water and food consumption and less than 15% for
the values of body weights. (A) The amounts of water consumed; (B) The amounts of food consumed; and (C) The body weights. *p, 0.05; ** p,0.01
vs. the GABA-fed mice.
doi:10.1371/journal.pone.0025338.g001
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+
macrophages in the adipose tissues indicated that the percentage
of macrophages infiltrated in the adipose tissues of the GABA-
treated mice was significantly less than that of the controls
(Fig. 4C). Collectively, these data clearly indicated that treatment
with GABA reduced the adipose tissue mass and macrophage
infiltrates in the adipose tissues of HFD-fed mice.
Oral treatment with GABA increases the frequency of
splenic Tregs in vivo
The Foxp3
+ Tregs are negative regulators of inflammatory
responses and recent studies have indicated that Tregs can inhibit
obesity-related inflammation and insulin resistance in mice
[12,23]. To further understand the mechanisms underlying the
actions of GABA in regulating the HFD-induced obesity and
insulin resistance, groups of C57BL/6 mice were fed with plain
water or water containing GABA (2 mg/ml) for 4 weeks and their
splenic CD4
+Foxp3
+ Tregs were characterized by flow cytometry
analysis. As shown in Fig. 5, there was no significant difference in
the frequency of CD4
+ T cells between the plain water-fed
controls and GABA-treated mice. However, the frequency of
CD4
+Foxp3
+ Tregs in the GABA-treated mice was significantly
higher than that of the controls (p,0.01). Therefore, treatment
with GABA increased the frequency of Tregs in mice.
Figure 2. Oral treatment with GABA improves glucose tolerance and insulin sensitivity in HFD-fed mice. Groups of C57BL/6 mice were
fed with HFD and given plain water or water containing 2 mg/ml of GABA for 20 weeks. The concentrations of fasting blood glucose, intraperitoneal
glucose tolerance (IPGT), and insulin sensitivity of individual mice were tested longitudinally, as described in the Materials and Methods. Data are
expressed as mean values of the concentrations of fasting blood glucose (A), the AUC of IPGT (B), and the percentages of blood glucose changes
following insulin challenge (C) in different groups of mice (n=20 for each group). *p, 0.05; ** p,0.01 vs. the GABA-fed mice.
doi:10.1371/journal.pone.0025338.g002
Figure 3. Oral treatment with GABA improves glucose tolerance and insulin sensitivity in mice after the onset of obesity and T2DM.
C57BL/6 mice were fed with HFD for 20 weeks and their fasting blood glucose and IPTG were measured. Individual mice with body weight .48g,
fasting glucose level of .145 mg/dL and abnormal IPTG (blood glucose .220 mg/dL at 2 hours post-IPGT) were considered to have obesity and
T2DM, and randomly treated orally with plain water (control) or water containing 2 mg/ml of GABA for another 12 weeks. Their body weights, fasting
glucose concentrations, IPGT and insulin sensitivity were measured longitudinally. (A) The body weights; (B) The concentrations of fasting blood
glucose; (C) The dynamic changes following glucose challenge; and (D) The percentages of blood glucose concentrations following insulin challenge.
Data are expressed as mean values of each group (n=4 per group) at the indicated time points and the concentrations of blood glucose before
insulin challenge in individual mice were used as 100%. *p, 0.05; ** p,0.01 vs. the GABA-fed mice.
doi:10.1371/journal.pone.0025338.g003
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Macrophage-related chronic inflammation in adipose tissues is
associated with the development of insulin resistance and glucose
intolerance, leading to the development of obesity and T2DM.
Our previous studies, and those of others, have shown that GABA,
through the activation of GABAA-R, inhibits inflammation in
mouse models of autoimmune diseases [16,17,18,19,20]. In this
study, we examined the impact of oral treatment with GABA on
the development of HFD-induced glucose intolerance and insulin
resistance as well as obesity in mice. We found that oral treatment
with GABA did not modulate the amount of food intake and water
consumption by mice, consistent with our previous findings [18].
Given that GABA has little or no ability to pass through the blood
brain barrier, it is not surprising that activation of peripheral
GABA receptors did not alter calorie intake in mice.
Furthermore, while most of the HFD-fed control mice displayed
a significant increase in body weights, the mice that had been fed
Figure 4. Oral treatment with GABA reduces adipocyte mass and macrophage infiltration in the adipose tissues of HFD-fed mice.
Groups of C57BL/6 mice were fed with HFD and provided with plain water or water containing 2 mg/ml of GABA for 20 weeks. The mice were
sacrificed and the amounts of VAT in individual mice were measured. One portion of the VAT was fixed with 4% paraformaldehyde for 24 hours and
the VAT sections at 5 mm were stained with Toluidine blue O, followed by examination under a light microscope. The sizes of adipocytes in 5 sections
of individual mice from each group (n=8) were examined in a blinded fashion. Another portion of VAT was fixed with the Bouin buffer for 48 hours
and the VAT sections were subjected to immunohistochemistry analysis of infiltrated macrophages using anti-F4/80 antibodies and DAB substrate
(brown), and the percentages of macrophages in 400 nuclear cells from 5 sections of each mouse in individual groups of mice were quantified in a
blinded manner. Data are representative images of the adipocytes, macrophages stained and expressed as mean 6 SEM from each group of mice
(n=8 for immunohistological examination and n=12 for measuring the amounts of VAT per group). *p, 0.05; ** p,0.01 vs. the GABA-fed mice.
doi:10.1371/journal.pone.0025338.g004
GABA Treatment for High Fat Diet-Fed Mice
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25338with HFD and GABA had significantly less gain in body weights
over the observation period. Over-consumption of calories can
cause obesity and lead to the development of insulin resistance and
T2DM [22,24]. We found that oral treatment with GABA
significantly improved glucose intolerance and insulin resistance in
HFD-fed mice. Evidentially, the levels of fasting blood glucose,
blood glucose at 2 hours post-glucose challenge, and the relative
levels of blood glucose post-insulin treatment in the GABA-treated
mice were significantly lower than that of the control mice. More
importantly, after the establishment of obesity and T2DM, oral
treatment with GABA significantly reduced the gain in body
weight and improved glucose tolerance and insulin sensitivity in
mice. These novel data demonstrated that oral treatment with
GABA not only prevented the HFD-induced obesity and T2DM
development, but also inhibited the progression of obesity and
T2DM in mice. Given that GABA is safe for human consumption,
GABA may be valuable for the prevention and treatment of
obesity and T2DM in the clinic.
Recent studies have shown that adipose tissue-related chronic
inflammation contributes to the development of insulin resistance,
a key component of metabolic syndrome, and leads to the
development of obesity and T2DM as well as other metabolic
disorder-related diseases [1,22]. To understand the potential
mechanisms underlying the therapeutic effect of GABA in
inhibiting the HFD-induced obesity and T2DM, we examined
the mass of adipose tissues and inflammatory infiltrates. In
comparison with that in the control mice, oral treatment with
GABA significantly reduced the total amounts of epididymal fat
tissues and the size of adipocytes in the HFD-fed mice. Because
macrophages are predominant players in the development of
chronic inflammation in adipose tissues [10,11,25,26,27], we
further characterized the frequency of macrophage infiltrates in
the epididymal fat tissues. We found that oral treatment with
GABA significantly decreased the frequency of macrophage
infiltrates in adipose tissues of the HFD-fed mice. More
importantly, GABAA receptor subunits are expressed by adipo-
cytes and macrophages, and GABAA receptor agonists can inhibit
macrophage activation [13,15,17]. It is possible that GABA,
through the GABAA receptors, inhibits macrophage activation
and migration, reducing chronic inflammation in adipose tissues.
Given that inflammatory adipocytes can produce adipokines that
recruit inflammatory infiltrates, such as macrophages, GABA may
alternatively inhibit adipogenesis and adipokine production,
indirectly limiting the macrophage infiltration into adipose tissue
in the HFD-fed mice. Recent studies have highlighted the
importance of glucagon in regulating glucose homeostasis
[28,29]. Physiologically, GABA acts synergistically with insulin
to inhibit the secretion of glucagon by the pancreatic a-cells, and
reverse insulin-deficiency-related hyperglycemia in mice [29,30].
Although we can not completely exclude the possible effect of
GABA-mediated inhibition of glucagon secretion, our data from
islet transplant suggest that treatment with GABA alone has little
ability to reverse T1D in diabetic NOD mice [19]. Hence, the
effect of GABA-mediated inhibition of glucagon secretion may be
minor in inhibiting HFD-induced glucose intolerance, insulin
resistance, and macrophage-related inflammation. Conceivably,
GABA, through its receptors, on macrophages and adipocytes,
improves glucose tolerance and insulin sensitivity in our
experimental model. We are interested in further investigating
how activation of GABAA receptors modulates adipogenesis and
macrophage activation and migration as well as adipokine and
cytokine production by adipocytes.
Notably, Tregs are potent inhibitors for macrophage activation
and function [23]. Tregs are negative regulators of obesity-related
insulin resistance and T2DM in mice [12,31]. We found that oral
treatment with GABA significantly increased the frequency of
splenic Tregs in C57BL/6 mice, indicating that GABA promoted
Treg proliferation and maturation in vivo. Our previous study has
shown that GABA, through the GABAA receptors, induces
effector T cell cycle arrest, consistent with the notion that
engagement of GABAA receptors induces the hyperpolarization
of membrane potentials, which may inhibit the TCR-related
signaling [16]. The significantly increased frequency of splenic
Tregs by GABA treatment suggests that GABA, through the
GABAA receptors, may promote the depolarization of membrane
potentials by opening the voltage-dependent calcium channel and
enhancing the TCR-triggering calcium-dependent downstream
survival and growth signaling [16,32]. Given that Tregs are potent
inhibitors of inflammation and insulin resistance the GABA-
induced increase in Tregs may also inhibit macrophage infiltration
and related chronic inflammation, contributing to the therapeutic
effect of GABA in inhibiting the HFD-induced obesity and
T2DM.
In summary, our data demonstrated that oral treatment with
GABA inhibited the HFD-induced obesity and improved glucose
intolerance and insulin sensitivity, even after the establishment of
obesity and T2DM in mice. Furthermore, oral treatment with
GABA reduced the HFD-induced adipocyte hypertrophy and
Figure 5. Oral treatment with GABA increases the frequency of splenic Tregs in vivo. C57BL/6 mice were fed with plain water or water
containing GABA (2mg/ml) for four weeks. Their splenic mononuclear cells were prepared and treated with anti-CD16/32. Subsequently, splenic
mononuclear cells (10
6/tube) were stained in duplicate with FITC-anti-CD4 and after washing, the cells were fixed, permeabilized and stained with PE-
anti-Foxp3, followed by flow cytometry analysis. The cells were stained with single fluorescent-labeled antibodies or with isotype-matched IgG as
controls. Data are representative charts and expressed as mean 6 SEM of the percentage of CD4
+Foxp3
+ Tregs in splenic CD4
+ T cells of different
groups of mice (n=3–4 mice per group) from two separate experiments. *p,0.01 vs. the water-fed mice.
doi:10.1371/journal.pone.0025338.g005
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macrophage infiltrates in the adipose tissues. Furthermore, we
found that GABA treatment increased the frequency of splenic
Tregs in mice. Apparently, GABA, through its GABAA-Rs on
adipocytes, macrophages and T cells, inhibited chronic inflam-
mation in adipose tissues, leading to the improvement of glucose
tolerance and insulin sensitivity in HFD-fed mice. Given that
GABA mainly acts on the peripheral GABA receptors and is safe
for human consumption, GABA and other GABAA-R agonists
may be valuable for the prevention and treatment of obesity and
T2DM in the clinic.
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